- Major pharmaceutical companies including Sanofi, Regeneron, Roche, Eli Lilly, Biogen, and Gilead are maintaining alliances and competing across key therapeutic areas like ophthalmology, immunology, and oncology.
- Sanofi, Regeneron, and Bayer are involved in new market developments, including FDA submissions regarding eczema and eye care treatments.
Regeneron, Bayer, and FDA are involved in the joint development of Eylea HD, following an FDA inspection of a third-party manufacturer.
2 reports, 1 independent
Updated Aug 21
Gone quiet
- Reports
- 2
- Developments
- 4
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Regeneron, Bayer, and FDA are involved in the joint development of Eylea HD, following an FDA inspection of a third-party manufacturer.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Regeneron recorded net product sales of Eylea in the US, and Bayer confirmed its collaboration on the drug's development.Sub-event
- Regeneron Pharmaceuticals and its team highlighted the strong commercial performance of key products and anticipated decisions regarding EYLEA HD and Libtayo use.Sub-event
- FDA inspection observations caused anticipated delays regarding Eylea HD, impacting Regeneron Pharmaceuticals and related development partners like Roche and Vabysmo.Sub-event
Joint development of Eylea HD and Regeneron's exclusive rights following FDA inspection.1 source
Keep exploring
The entities involved
- FDA
-
Regeneron Pharmaceuticals
American pharmaceutical company
-
Bayer
German multinational pharmaceutical, chemical, and agricultural biotechnology company
Nothing else this week.
Related events
- Mylan is seeking regulatory approval from the FDA for new products and has listed its stock on the Nasdaq exchange.
- Biocon's subsidiary received FDA approval for a drug in the United States on August 18, 2026.
- Unicycive Therapeutics, Inc. is facing investigator findings regarding manufacturing compliance issues from the FDA.
- Elutia is trading on the Nasdaq stock exchange and requires regulatory clearance from the FDA for product launches.
- FDA and Pfizer are seeking regulatory approval for their products.
Coverage
Newest first; wire copies grouped- ZacksFDA Extends Review Period of REGN's Submission for Eylea HD Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has extended the target action dates for Eylea HD (aflibercept) injection 8 m
- ZacksRegeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up Regeneron Pharmaceuticals, Inc. (REGN) reported second-quarter 2025 adjusted earnings per share (EPS) of $12.89, which comfortab